Headlines about Stemline Therapeutics (NASDAQ:STML) have been trending somewhat positive recently, Accern reports. Accern ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Stemline Therapeutics earned a news impact score of 0.18 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 45.9737381788942 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

STML has been the subject of a number of research analyst reports. HC Wainwright reiterated a “buy” rating and issued a $34.00 target price on shares of Stemline Therapeutics in a report on Tuesday, March 28th. Cowen and Company reiterated a “buy” rating on shares of Stemline Therapeutics in a report on Friday, May 12th. Jefferies Group LLC reiterated a “buy” rating and issued a $16.00 target price on shares of Stemline Therapeutics in a report on Thursday, May 25th. Wedbush restated an “outperform” rating and set a $11.00 price objective on shares of Stemline Therapeutics in a report on Saturday, March 25th. Finally, Zacks Investment Research downgraded Stemline Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday. Two research analysts have rated the stock with a sell rating and seven have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $29.17.

Shares of Stemline Therapeutics (NASDAQ STML) opened at 9.85 on Thursday. The stock’s 50 day moving average price is $8.68 and its 200 day moving average price is $8.80. Stemline Therapeutics has a 12-month low of $5.50 and a 12-month high of $14.60. The company’s market cap is $230.25 million.

Stemline Therapeutics (NASDAQ:STML) last posted its quarterly earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.45) by $0.22. Stemline Therapeutics had a negative net margin of 3,864.20% and a negative return on equity of 60.51%. The business had revenue of $0.30 million during the quarter, compared to analysts’ expectations of $0.30 million. On average, analysts forecast that Stemline Therapeutics will post ($2.27) EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Stemline Therapeutics (STML) Receiving Somewhat Positive Press Coverage, Analysis Finds” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another publication, it was stolen and republished in violation of U.S. and international trademark & copyright laws. The correct version of this report can be read at https://www.thecerbatgem.com/2017/07/20/stemline-therapeutics-stml-receiving-somewhat-positive-press-coverage-analysis-finds.html.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Insider Buying and Selling by Quarter for Stemline Therapeutics (NASDAQ:STML)

Receive News & Stock Ratings for Stemline Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc. and related stocks with our FREE daily email newsletter.